- Home
- KIM vs ZBH Comparison
KIM vs ZBH Comparison
Compare KIM & ZBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KIM | ZBH |
|---|---|---|
| Founded | 1958 | 1927 |
| Country | United States | United States |
| Employees | 710 | N/A |
| Industry | Real Estate Investment Trusts | Industrial Specialties |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.5B | 16.0B |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | KIM | ZBH |
|---|---|---|
| Price | $24.23 | $87.33 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 14 | 21 |
| Target Price | $25.00 | ★ $101.00 |
| AVG Volume (30 Days) | ★ 3.4M | 2.0M |
| Earning Date | 04-30-2026 | 04-28-2026 |
| Dividend Yield | ★ 4.40% | 1.20% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.22 |
| Revenue | N/A | ★ $8,231,500,000.00 |
| Revenue This Year | $3.31 | $4.96 |
| Revenue Next Year | $3.57 | $3.76 |
| P/E Ratio | ★ $27.76 | $71.07 |
| Revenue Growth | N/A | ★ 7.20 |
| 52 Week Low | $19.76 | $79.12 |
| 52 Week High | $24.62 | $108.29 |
Technical Indicators
Market Signals| Indicator | KIM | ZBH |
|---|---|---|
| Relative Strength Index (RSI) | 59.55 | 56.45 |
| Support Level | $22.91 | $85.38 |
| Resistance Level | $24.62 | $87.22 |
| Average True Range (ATR) | 0.41 | 2.18 |
| MACD | 0.01 | 0.60 |
| Stochastic Oscillator | 76.37 | 73.91 |
Price Performance
Historical ComparisonAbout KIM Kimco Realty Corporation (HC)
One of the oldest real estate investment trusts in the United States, Kimco Realty owns interests in 565 shopping centers throughout major markets in the US, representing roughly 100 million square feet.
About ZBH Zimmer Biomet Holdings Inc.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.